Roliten
✅ Reduces urinary frequency
✅ Controls urge incontinence
✅ Relieves bladder spasms
✅ Parantaa virtsan virtausta
✅ Enhances bladder control
Roliten contains Tolterodine.
✓ Lääketieteellinen tarkistus Morgan Ellis — Farmasian tutkija · 8 vuoden kokemus · Viimeisin arvio: toukokuu 2026
Quick Answer — What is Roliten?
Roliten sisältää tolterodine tartrate — a competitive muscarinic acetylcholine receptor antagonist used to treat overactive bladder (OAB) with urgency, frequency, and urge incontinence. Available as 1 mg immediate-release tablets. Standard dose: 2 mg twice daily (or 1 mg twice daily in renal/hepatic impairment or with strong CYP3A4 inhibitors). For convenient once-daily dosing with smoother side-effect profile, see the extended-release formulation (Terol LA). Tolterodine is generally better tolerated than oxybutynin — less dry mouth, less constipation, and lower CNS penetration. Use with caution in adults aged 65+ — the 2023 American Geriatrics Society Beers Criteria classifies all anticholinergic OAB drugs as “potentially inappropriate” in older adults due to cumulative anticholinergic burden. Mirabegron (Mirago) is the preferred first-line OAB drug in this population.
📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.
Miksi tilata MedsBasesta
Jokainen erä on hankittu WHO-GMP sertifioitu valmistaja. Tilaukset toimitetaan yksinkertaisessa, brändittömässä pakkauksessa täyttöpartneriemme kautta ja niihin kuuluu Reshipment Assurance Policy -politiikkamme piiriin: jos lähetys ei saavu 20 arkipäivän kuluessa, lähetämme uuden ilmaiseksi, kysymättä lisäkysymyksiä.
What is Roliten?
Roliten is a brand of tolterodine tartrate 1 mg immediate-release tablets. Tolterodine is one of the most-prescribed antimuscarinic OAB drugs worldwide. Internationally branded as Detrol / Detrol LA (US), Detrusitol / Detrusitol XL (UK / EU). Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets/capsules.
How tolterodine works
Tolterodine is a competitive antagonist at M2 and M3 muscarinic acetylcholine receptors. Bladder M3 blockade reduces parasympathetic-driven detrusor contractions during the filling phase — decreasing urgency and incontinence episodes and increasing functional bladder capacity.
Compared to oxybutynin, tolterodine has somewhat better selectivity for bladder vs salivary-gland muscarinic receptors, lower CNS penetration, and a more favourable side-effect profile — particularly less severe dry mouth. Both are still anticholinergics with the standard class warnings about elderly use.
Tolterodine is metabolised by CYP2D6 to an active metabolite (5-hydroxymethyl tolterodine) which contributes substantially to clinical effect. About 5-10% of the population are CYP2D6 “poor metabolisers” who form less of the metabolite and need dose adjustment.
When tolterodine is used
- Overactive bladder syndrome (OAB) with urgency, frequency, urge incontinence, nocturia — the licensed indication
- Neurogenic detrusor overactivity — selected adult cases (multiple sclerosis, spinal cord injury)
- Patients intolerant of oxybutynin — tolterodine is a common second-choice antimuscarinic with slightly better tolerability
- OAB combination therapy with mirabegron — for refractory OAB symptoms in patients who tolerate but don’t fully respond to either alone
Annostelu ja käyttöohjeet
- Standard adult dose: 2 mg twice daily
- Reduced dose 1 mg twice daily for: significant renal impairment (eGFR <30), moderate hepatic impairment, concurrent strong CYP3A4 inhibitors, or patients poorly tolerating 2 mg twice daily
- Take with or without food, with water. Swallow tablets whole.
- For more convenient once-daily dosing, ask your doctor about Terol LA (extended-release tolterodine 2 mg / 4 mg capsules)
- Effect develops over 4-8 weeks. If no benefit by 8 weeks, switch to a different agent.
Sivuvaikutukset ja turvallisuus
- Yleiset (1/10): dry mouth (less severe than oxybutynin but still the leading reason for discontinuation), constipation, dry eyes, blurred vision, headache, dyspepsia, fatigue
- Vähemmän yleisiä: drowsiness, dizziness, peripheral oedema, urinary retention or hesitancy, dry skin, weight gain
- Vähemmän yleisiä mutta tärkeitä: confusion, hallucinations (especially in elderly), QT prolongation (caution if QT-prolonging co-medications)
- Harvinainen mutta vakava: acute angle-closure glaucoma, severe constipation / paralytic ileus, urinary retention, anaphylaxis, angioedema
Anticholinergic burden & the elderly
Tolterodine has somewhat lower CNS penetration than oxybutynin and is generally considered the better-tolerated of the two anticholinergic OAB drugs in older adults — but it is still classified as “potentially inappropriate” in the Beers Criteria and should be used cautiously and at the lowest effective dose. Mirabegron remains the preferred first-line OAB drug in adults aged 65+ when affordable and not contraindicated by hypertension.
Kontraindikaatiot ja varoitukset
Do not take tolterodine if you have:
- Untreated narrow-angle glaucoma
- Urinary retention or significant bladder outlet obstruction
- Severe gastrointestinal motility disorders (paralytic ileus, severe ulcerative colitis, toxic megacolon)
- Myasthenia gravis
- Vakava maksatoimintavajaus
- Hypersensitivity to tolterodine or fesoterodine (its prodrug)
Käytä varovaisesti, jos sinulla on: elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, congenital or acquired QT prolongation, coronary artery disease.
Lääkevuorovaikutukset
- Voimakkaat CYP3A4-estäjät (ketoconazole, itraconazole, ritonavir, clarithromycin, indinavir) — sharply increase tolterodine levels; reduce dose to 1 mg BD (IR) or 2 mg OD (LA)
- Other anticholinergics — additive effects; minimise stacking (diphenhydramine, hydroxyzine, amitriptyline, paroxetine, quetiapine, hyoscyamine, oxybutynin)
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine for dementia) — opposing mechanisms; co-prescribing both is irrational
- QT-aikaa pidentävät lääkeaineet (Luokan Ia/III antiarytmit, jotkut antipsykootit, kinoloniantibiootit) — teoreettinen additiivinen riski
- CYP2D6 substrate medications — tolterodine is metabolised by CYP2D6, so poor metabolisers (5-10% of population) have higher exposure
How tolterodine compares
| Lääkeaine | Huomionarvoinen piirre |
|---|---|
| Oxybutynin | Older, cheaper; highest dry mouth + cognitive risk |
| Tolterodine IR / LA | Better tolerated than oxybutynin; LA gives once-daily dosing |
| Solifenacin / darifenacin | More M3-selective; slightly less dry mouth |
| Mirabegron | β3 agonist — preferred first-line in 65+; no anticholinergic burden |
| Flavoxate (Urispas) | Antispasmodic; useful for urinary spasm post-procedure |
Säilytys ja käyttöikä
Store Roliten below 25°C in the original blister pack. Protect from moisture and light. Keep out of reach of children. Do not use after the expiry date.
Usein Kysytyt Kysymykset
What’s the difference between Roliten (IR) and Terol LA (extended-release)?
Same active ingredient (tolterodine tartrate), different release profile. Roliten 1 mg twice daily uses immediate-release tablets — cheaper, more flexible dose adjustment, but plasma peaks-and-troughs cause more variable side effects. Terol LA 4 mg once daily uses an extended-release capsule — flatter plasma curve translates into modestly less dry mouth, simpler regimen (better adherence). Choose IR if you need finer dose titration or are titrating cautiously; switch to LA when you find a stable dose.
Why does tolterodine cause dry mouth?
Tolterodine blocks the M3 muscarinic receptors that drive saliva production — the same receptor it blocks in the bladder. Side-effect mitigation: sugar-free chewing gum, frequent sips of water, saliva substitute (Biotene). If dry mouth is intolerable, mirabegron (Mirago) avoids the antimuscarinic mechanism altogether.
How long until tolterodine works?
Initial improvement in urgency and frequency is typically noticeable within 1-2 weeks; full effect over 4-8 weeks. If no benefit by 8 weeks at the maximum tolerated dose, switching to a different OAB drug (mirabegron, solifenacin) is reasonable.
Can I take tolterodine if I am over 65?
The 2023 American Geriatrics Society Beers Criteria classifies all anticholinergic OAB drugs as “potentially inappropriate” in older adults. Tolterodine is somewhat better tolerated than oxybutynin but still carries the anticholinergic burden risk — falls, cognitive slowing, possible long-term dementia association. Discuss mirabegron first with your doctor; it has equivalent efficacy without these risks.
Can I take tolterodine with mirabegron?
Yes — combination therapy with a low-dose anticholinergic plus mirabegron is well-evidenced for refractory OAB symptoms (BESIDE-style data). Monitor for urinary retention, particularly in men with bladder outlet obstruction.
Will tolterodine affect my driving or work?
Drowsiness, dizziness, and blurred vision can affect driving or operating machinery. Avoid until you know how the medication affects you. Effects typically settle after the first 1-2 weeks.
Where can I order Roliten online?
You can order Roliten from MedsBase in standard pack sizes. Orders ship worldwide with discreet packaging. Tolterodine is specialist-supervised worldwide.
Aiheeseen liittyvät vaihtoehdot
Muut tuotteet Yleinen terveys joita asiakkaat myös katsovat:
Lisää vaihtoehtoja virtsarakon ja eturauhasen hoitoon
Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.
| Vahvuus | 1 mg |
|---|---|
| Määrä | 30 tablettia, 60 tablettia, 90 tablettia, 180 tablettia |
Roliten
Kysymykset ja vastaukset
Roliten
Liittyvät tuotteet
Arvostelut
Ei vielä arvosteluja